SmithKline Beckman Corp. announced that it will...

SmithKline Beckman Corp. announced that it will invest $49 million in a partnership with Nova Pharmaceutical Corp. to develop new therapies for the treatment of central nervous system diseases. Philadelphia-based SmithKline also agreed, in a separate action, to collaborate with Nova in the development, manufacture and marketing of Nova’s bradykinin antagonist drugs, which Nova is testing as a treatment for common cold symptoms.